Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDU6GN)

Drug Name

JNJ-479655 Drug Info

Synonyms

1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, > Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Clinical trial	[1]

Cross-matching ID

PubChem CID: 66553218
TTD Drug ID: DMDU6GN

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting P2X purinoceptor 7 (P2RX7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CE-224535	DMFCLT6	Arthralgia	ME82	Phase 2/3	[3]
AZD9056	DMJGYPK	Chronic obstructive pulmonary disease	CA22	Phase 2	[4]
LY3857210	DMZO2V2	Pain	MG30-MG3Z	Phase 2	[5]
BIL010t	DMV1EA9	Alzheimer disease	8A20	Phase 1/2	[6]
EVT 401	DMOG8IE	Rheumatoid arthritis	FA20	Phase 1	[7]
SGM-1019	DMDAHEL	Inflammatory bowel disease	DD72	Phase 1	[8]
GSK1482160	DMWDQOV	Pain	MG30-MG3Z	Phase 1	[9]
JNJ-55308942	DM0QZJX	Anhedonia	MB24.2	Phase 1	[6]
JNJ-54175446	DMQ5ZVK	Major depressive disorder	6A70.3	Phase 1	[10]
Quinoline derivative 12	DM9FXE7	N. A.	N. A.	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2X purinoceptor 7 (P2RX7)	TT473XN	P2RX7_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci. 2013 Mar;53:52-62.
2	Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.
3	Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
4	Clinical pipeline report, company report or official report of AstraZeneca (2009).
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
6	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
7	Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.